Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Lenalidomide
État du projet:
Terminé
Domaine thérapeutique:
Multiple Myeloma, newly diagnosed
Fabricant:
Celgene Inc.
Brand Name:
Revlimid
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0061-000
Strength:
5, 10, 15, 25 mg capsules
Tumour Type:
Myeloma
Indications:
Multiple Myeloma (newly diagnosed)
Funding Request:
In combination with low-dose dexamethasone, for treatment of newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016